A recent Journal of the American Medical Association article has reignited controversy surrounding marijuana rescheduling, revealing that the Biden Administration’s 2023 recommendation was based more on politics than science.

The study shows that moving cannabis from Schedule I to Schedule III classification lacks proper scientific foundation, raising serious questions about the reclassification process and its implications for public health.

Understanding Drug Scheduling Classification

Drug schedules represent a federal system for designating controlled substances, not simply an index of how “bad” a drug is. This explains why marijuana and heroin both appear on Schedule I despite their different effects.

The marijuana rescheduling debate centres on specific criteria including whether the drug has currently accepted medical use, high abuse risk, and poses threats to public health. Substances lacking medical value with high abuse potential receive Schedule I classification.

Medical Use Claims Under Scrutiny

Despite common belief, cannabis reclassification advocates face a significant hurdle: no federal agencies recognise any medical condition for which marijuana serves as an accepted treatment. Whilst some medicines derive from marijuana chemicals, the drug itself lacks recognised medical use.

State medical programmes permitting doctor recommendations represent political rather than scientific decisions. These programmes don’t provide evidence supporting reclassification, as majority votes cannot change scientific facts.

A commonly cited 2017 study suggesting marijuana treats chronic pain has been contradicted by dozens of subsequent analyses. Across the medical field, evidence supporting cannabis reclassification remains weak.

Public Health Threats from Cannabis Use

Research demonstrates marijuana poses serious public health risks, contradicting arguments favouring marijuana rescheduling. Studies reveal the drug causes heart damage, raises dementia risks, and increases chances of developing serious mental illness.

Statistics comparing cannabis abuse prevalence, particularly among young people, against total user numbers show marijuana is more addictive than alcohol—a substance often used for comparison by rescheduling advocates.

Federal traffic safety data highlight another concern: marijuana impairment lasts five times longer than alcohol impairment. Nearly 56% of drivers testing positive for drugs after serious or fatal crashes had marijuana in their systems, undermining arguments for marijuana rescheduling.

Research Access Arguments Questioned

Marijuana rescheduling supporters claim current classification restricts scientific research. However, moving cannabis to Schedule III would likely have zero real effect on research capabilities.

This raises questions about the true motivations behind marijuana rescheduling efforts if improved research access isn’t a genuine outcome.

Commercial Motivations Behind Rescheduling Push

The marijuana rescheduling movement appears driven by two clear commercial interests rather than public health concerns.

Schedule III classification would allow cannabis businesses to claim regular tax deductions on expenses related to growing and selling marijuana, including advertising costs. This means companies producing cannabis gummies designed to resemble children’s sweets could write off these marketing expenses.

Such changes would supercharge the existing cannabis industry, potentially opening doors for major addiction profiteers from tobacco and alcohol industries to enter the marijuana market.

Industry Legitimacy Through Rescheduling

The second motivation behind marijuana rescheduling involves public relations benefits. Reclassification sends a message that dangerous, psychoactive drugs are actually acceptable because “the government said so.”

This legitimacy boost serves commercial interests by reducing public health concerns about cannabis products, potentially expanding market reach and user base.

The Real Agenda Behind Rescheduling

Analysis of the marijuana rescheduling push reveals two primary drivers: financial gain and public relations advantages. The movement appears motivated by money and marketing rather than genuine scientific advancement or public health improvement.

The Biden Administration’s 2023 marijuana rescheduling recommendation, shown by recent research to prioritise politics over science, exemplifies how commercial pressures can influence drug policy decisions.

Implications for Drug Policy

The marijuana rescheduling controversy demonstrates how political considerations can override scientific evidence in substance regulation. The Journal of the American Medical Association study provides clear evidence that proper scientific standards weren’t followed in developing rescheduling recommendations.

This situation raises broader questions about maintaining scientific integrity in drug classification systems designed to protect public health from harmful substances.

Source: The Drug Report